See other companies on Welcome to the Jungle
BillionToOne
Precision diagnostics for disease detection
- 201-500 employees
- Healthcare
- B2B
- Biology
- MedTech
- Menlo Park, CA
Jump to section
Company mission
To make molecular diagnostics more accurate, efficient, and accessible.
Our take
BillionToOne is a precision diagnostics company. Its proprietary molecular counting platform (Quantitative Counting Templates) accurately counts DNA molecules at the single-count level, which has the ability to significantly improve disease detection. While initially focused on prenatal screening and oncological liquid biopsies, the company’s QTC technology is highly scalable and has the ability to make vast improvements to a range of disease detection verticals.
The company’s funding efforts will enable it to focus on further development and commercialization of its noninvasive prenatal screening test and oncology products. However, it will need to maintain a strategic outlook, prioritizing areas with higher testing frequencies in order to provide maximum patient benefit, while balancing test development costs.
BillionToOne has an important role to play in improving healthcare equity. As more promising peer-reviewed research studies are conducted and providers have increased confidence in the company’s tests, BillionToOne has significant growth potential.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Suite of benefit plans
- Paid Medical, Pregnancy, Parental and Family Leaves
- Latest and greatest hardware (laptop, lab equipment, facilities)
- Retirement savings program with Company contribution
- Generous equity package
- Free daily on-site lunches provided from top eateries
- Free on-site EV charging (compatible with all EVs, including Tesla!)
- Working with a team of ‘rockstars’ who bring out the best in everyone
- The ability to indirectly or directly change the lives of hundreds of thousand patients
- Open, transparent culture that includes weekly Town Hall meetings
Company values
- Profoundly Impactful
- Creative & Innovative
- Internally Motivated & Passionate
- Rational & Deliberate
- Kindly Inquisitive & Collaborative
- Patient-Centered
Funding (last 2 of 4 rounds)
Dec 2022
$5m
SERIES B
Mar 2022
$21m
SERIES B
Total funding: $43.3m
Leadership
Oguzhan Atay, PhD
(CEO)Former Graduate Fellow at Stanford University (Department of Biology). They also spent time as a Researcher at the University of Oxford.
David Tsao
(CTO)Former Technical Staff Member at Groupon and Software Engineer at Adku. They also worked as an Engineering Intern at Northrop Grumman Aerospace Systems.
Articles
Jobs (4)
Data
Operations & Strategy
Product
Other Engineering